Drug news
NICE does not recommend Vargetef for treatment of Non Small Cell Lung Cancer- Boehringer
The National Institute of Care and Health Excellence (NICE) has in draft guidance not recommended Vargetef (nintedanib) from Boehringer as a treatment for Non Small Cell Lung Cancer as it is not cost effective. Vargetef, an oral triple angiokinase inhibitor, was approved in Europe in November 2014 for the treatment of locally advanced, metastatic or locally recurrent Non-Small Cell Lung Cancer of adenocarcinoma tumor histology after first-line chemotherapy, in combination with docetaxel.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.